Yubo International Biotech Limited
YBGJ
$0.01
$0.01120.41%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 197.67% | -- | -- |
| Gross Profit | -- | -- | 90.70% | -- | -- |
| SG&A Expenses | -16.91% | -42.17% | -45.85% | -39.41% | -18.63% |
| Depreciation & Amortization | -97.78% | -34.75% | 4.72% | -12.10% | 0.67% |
| Other Operating Expenses | 251.03% | -4.96% | 212.13% | -69.34% | -120.94% |
| Total Operating Expenses | -4.33% | -38.09% | -15.64% | -50.07% | -58.27% |
| Operating Income | 4.33% | 38.09% | 19.12% | 50.07% | 58.27% |
| Income Before Tax | -7.61% | 36.87% | 19.04% | 50.06% | 58.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.61% | 36.87% | 19.04% | 50.06% | 58.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 7.22% | -29.34% | -61.71% | -16.92% | -72.60% |
| Net Income | -7.64% | 37.42% | 9.77% | 52.34% | 56.34% |
| EBIT | 4.33% | 38.09% | 19.12% | 50.07% | 58.27% |
| EBITDA | -16.28% | 38.44% | 22.41% | 53.47% | 62.95% |
| EPS Basic | 21.05% | 55.56% | 37.50% | 60.42% | 56.82% |
| Normalized Basic EPS | 18.18% | 54.55% | 30.77% | 62.07% | 56.00% |
| EPS Diluted | 21.05% | 55.56% | 37.50% | 60.42% | 56.82% |
| Normalized Diluted EPS | 18.18% | 54.55% | 30.77% | 62.07% | 56.00% |
| Average Basic Shares Outstanding | 42.23% | 42.23% | 42.51% | 23.41% | 0.00% |
| Average Diluted Shares Outstanding | 42.23% | 42.23% | 42.51% | 23.41% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |